Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
boston
boston blog main
boston top stories
clinical trials
deals
fda
san diego blog main
san diego top stories
san francisco blog main
abide therapeutics
akouos
allergan
amylin pharmaceuticals
astellas pharmaceuticals
azacitidine
ben cravatt
beta-thalassemia
biotech ipos
botox
bristol-myers squibb
business
business sponsored company news
california institute for biomedical research
dacogen
decibel therapeutics
decitabine
dna
dyne therapeutics
epigenetics
epilepsy
epizyme
executives
farydak
flagship pioneering
frequency therapeutics
fulcrum therapeutics
gabapentin
What
developing
5
×
medicines
5
×
therapeutics
5
×
biotech
company
drug
ipo
million
treat
abide
affects
aims
americans
announced
appointed
approach
approved
based
breakthrough
brings
called
chief
completion
date
debuts
dedicated
diseases
disorders
drugs
dyne
dyne’s
epigenetic
epigenetics
executive
fda
field
financing
finney
flagship’s
frequency
Language
unset
Current search:
developing
×
therapeutics
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@venturebeat.com
6 years ago
Relay Therapeutics Secures $63 Million in Series B Financing
